Acadia Pharmaceuticals Stock
Price
Target price
€15.62
€15.62
1.450%
0.22
1.450%
€32.44
26.04.24 / Tradegate
WKN: 603035 / Symbol: ACAD / Name: ACADIA Pharm / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals gained 1.450% today.
The stock is one of the favorites of our community with 22 Buy predictions and 1 Sell predictions.
With a target price of 32 € there is potential for a 104.93% increase which would mean more than doubling the current price of 15.62 € for Acadia Pharmaceuticals.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | 1.450% | -1.731% | -5.364% | -14.672% | -45.018% | -11.505% | -33.849% |
| Novocure Ltd | 3.070% | 4.053% | -2.114% | -79.652% | -17.268% | -93.443% | - |
| Sage Therapeutics Inc. | -0.350% | 2.037% | -26.156% | -70.428% | -36.125% | -80.292% | - |
| Iovance Biotherapeutics Inc. | -1.440% | 2.211% | -16.359% | 119.362% | 39.152% | -60.289% | - |
Comments
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $25.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
